Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in Healthcare

CanSino's COVID-19 Vaccine Candidate Approved For Military Use In China

China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year,

Read More

Japan's Takeda Expects $200 Million Operating Loss Related To Novartis' Xiidra Withdrawal

Takeda sold Xiidra to Novartis for $3.4 billion upfront and up to an additional $1.9 billion in potential milestone receipts.

Read More

Carlyle Group To Buy 20% Stake In Piramal Pharma For Over Rs 3,700 Cr

The capital raise will accelerate Piramal Pharma's organic and inorganic growth plans,

Read More

Vaccine Makers Face Biggest Medical Manufacturing Feat In History

J&J has partnered with the U.S. government on a $1 billion investment to speed development and production of its vaccine, even before it's proven to work.

Read More

Vaccine Alliance Finds Manufacturing Capacity For 4 Bln Doses Of Coronavirus Vaccines

CEPI has deployed up to $829 million so far in the search for a COVID-19 vaccine through partnerships with nine developers, with the hope that at least some will be successful.

Read More

India's Hetero Prices Experimental COVID-19 Drug Remdesivir At $71 Per 100 mg Vial

Fellow Indian drug firm Cipla Ltd had said on Tuesday that its own version of the antiviral drug remdesivir would be priced below Rs 5,000

Read More

India's Hetero Prices Experimental COVID-19 Drug Remdesivir At $71 Per 100 Mg Vial

India has approved the generic versions made by Cipla and Hetero for restricted emergency use in severe COVID-19 cases.

Read More

Inovio Gets $71 Million From U.S. Defense Dept For COVID-19 Vaccine Device

Inovio said a previous version of the device has been used in clinical trials to safely dose more than 2,000 patients

Read More

Cipla To Price Remdesivir Version For COVID-19 Under 5,000 Rupees

The expectations suggest sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course, according to Jefferies analyst Michael Yee.

Read More

Pig Trial Of AstraZeneca's COVID-19 Vaccine Shows Promise With Two Shots

The researchers saw a marked increase in neutralising antibodies, which bind to the virus in a way that blocks infection," the Pirbright team said in a statement.

Read More

Sanofi Eyes Approval Of COVID-19 Vaccine By First Half Of 2021

There are currently no vaccines to prevent the coronavirus that has infected more than 9 million people and killed over 469,000 globally, and only a couple of medicines that have demonstrated benefit in hospitalized COVID-19 patients in clinical trials.

Read More

Sanofi Eyes Approval Of COVID-19 Vaccine By First Half Of 2021

Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.

Read More

Gilead Targets Remdesivir Supply For Two Million COVID-19 Patients By Year-End

Gilead's expectations of two million treatment courses suggests sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course

Read More

GSK In Quest To Be Best, Not First, In Race For COVID-19 Vaccine

GSK is one of more than 100 global players working on vaccines against COVID-19, which has killed about 350,000 people.

Read More

Alembic Pharma Gets EIR From USFDA For Its Panelav Facility

Shares of Alembic Pharmaceuticals were trading at Rs 940.05 per scrip on the BSE, up 3.50 per cent from its previous close.

Read More